논문검색
Author Jun Yong Park, M.D.1, Chul Kim, M.D.1,2,3, Joo Hyuk Sohn, M.D.1,2,3,4, Yong Tae Kim, M.D.1,2,3,4, Sun Young Rha, M.D., Ph.D.2,3,4, Woo Ick Jang, M.D., Ph.D.5, Gwi Eon Kim, M.D., Ph.D.2,3,4 and Hyun Cheol Chung, M.D., Ph.D.1,2,3,4
Place of duty Departments of 1Internal Medicine, 2Yonsei Cancer Center, 3Cancer Metastasis Research Center, 4Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 5Lilly Korea Ltd., Seoul, Korea
Title A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane
Publicationinfo Cancer Research and Treatment 2002 Aug; 034(04): 274-279.
Key_word Metastatic breast neoplasm, Chemotherapy, Gemcitabine
Full-Text
Abstract Purpose: We performed a phase II trial to evaluate the efficacy and the safety of gemcitabine monotherapy, a pyrimidine antimetabolite, in patients, who had previously failed anthracycline and taxane-based chemotherapy for the treatment of metastatic breast cancer.

Materials and Methods: Twenty-one patients with metastatic breast cancer, which was unresponsive to previous chemotherapy, were entered into this study. Gemcitabine was administered at 850 mg/m2, as a 60- minute intravenous infusion on days 1, 8 and 15. This regimen was repeated every 28 days with G-CSF support, but without dose reduction.

Results: Objective responses were seen in 6 of the 20 patients who were able to be evaluated (1 complete response and 5 partial responses), with an objective response rate of 30%. The median time to progression

was 5 (1∼20) months, and the median overall survival duration was 11 (2∼21) months. The actual dose intensity was 566.7 mg/m2/wk (range; 340∼637.5 mg/m2/wk) and the relative dose intensity was 0.89 (range; 0.40∼1.00). Toxicity was mainly hematological. Toxicities included: grade 3 neutropenia in 20% and anemia in 5%. Grades 3 and 4 thrombocytopenia occurred in 15% of the patients.

Conclusion: Gemcitabine monotherapy is an effective and safe treatment for refractory breast cancer patients heavily treated with the anthracycline and taxane- based regimen. Cancer Research and Treatment 2002;34:274⁣279)

저 자 박준용, 김철, 손주혁, 김용태, 라선영, 장우익, 김귀언, 정현철